ReviewInternational journal of obesity (2005)2020
Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice.
Review in International journal of obesity (2005), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anti-Obesity Therapeutic Targets Studied In Silico and In Vivo: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Overactivation of the Endocannabinoid System in Adolescence Disrupts Adult Adipose Organ Function in Mice.Cells · 2024Article
- Characterization of the effects of cannabinoid receptor deletion on energy metabolism in female C57BL mice.Frontiers in endocrinology · 2024Article
- Adolescent exposure to low-dose THC disrupts energy balance and adipose organ homeostasis in adulthood.Cell metabolism · 2023Article
- Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity.Biomedicines · 2023Review
- The CB1 cannabinoid receptor regulates autophagy in the tibialis anterior skeletal muscle in mice.Biological research · 2023Article
- In Vitro and In Silico Studies of Neolignans fromMolecules (Basel, Switzerland) · 2023Article
- G protein-coupled receptors and obesity.Frontiers in endocrinology · 2023Review
- Cross-Talk between the (Endo)Cannabinoid and Renin-Angiotensin Systems: Basic Evidence and Potential Therapeutic Significance.International journal of molecular sciences · 2022Review
- Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors.Frontiers in pharmacology · 2022Article
- The Peripheral Cannabinoid Receptor Type 1 (CBMolecules (Basel, Switzerland) · 2021Review
- Cannabinoid receptors distribution in mouse cortical plasma membrane compartments.Molecular brain · 2021Article
- Review
- Quality of Life and a Surveillant Endocannabinoid System.Frontiers in neuroscience · 2021Review
- Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human.Frontiers in endocrinology · 2021Article
- The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation.Frontiers in pharmacology · 2021Review
- Possible Role of Adipose Tissue and the Endocannabinoid System in Coronavirus Disease 2019 Pathogenesis: Can Rimonabant Return?Obesity (Silver Spring, Md.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological blockers of the cannabinoid receptor type-1 (CB1) have been considered for a long time as the holy grail of obesity pharmacotherapy. These agents were hastily released in the clinical setting, due to their clear-cut therapeutic efficacy. However, the first generation of these drugs, which were able to target both the brain and peripheral tissues, had serious neuropsychiatric effects, leading authorities to ban their clinical use. New peripherally restricted CB1 blockers, characterized by low brain penetrance, have been developed over the past 10 years. In preclinical studies, these molecules seem to overcome the neuropsychiatric negative effects previously observed with brain-penetrant CB1 inhibitors, while retaining or even outperforming their efficacy. The mechanisms of action of these peripherally restricted compounds are only beginning to emerge, and a balanced discussion of the risk/benefits ratio associated to their possible clinical use is urgently needed, in order to avoid repeating past mistakes. Here, we will critically discuss the advantages and the possible hidden threats associated with the use of peripheral CB1 blockers for the pharmacotherapy of obesity and its associated metabolic complications. We will address whether this novel pharmacological approach might 'compete' with current pharmacotherapies for obesity and diabetes, while also conceptualizing future CB1-based pharmacological trends that may significantly lower the risk/benefits ratio associated with the use of these drugs.
Indexed as
Identifiers
32317751What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.